Tony McHale standing in his garden, smiling.

Help every man with prostate cancer

Give the gift of research to help every man with prostate cancer live longer, healthier lives.

Donate now

Tony McHale (pictured above) discovered he had an alteration in the BRCA2 gene at the age of 61, putting him at a much higher risk of developing prostate cancer. Shortly after, Tony joined the IMPACT study at the ICR, which investigated whether regular screening would lead to earlier diagnosis of aggressive forms of the disease. Around 18 months later, the screening revealed Tony had prostate cancer. 

"Being involved in the IMPACT study saved my life. If I hadn't taken part, I'd never have known I had prostate cancer. As far as I was aware, I didn't have any symptoms – and the sooner the disease is detected and treated, the better the chances are of survival." – Tony

Godfrey's prostate cancer story

 

DJ and music promoter, Godfrey Fletcher, found out he had prostate cancer in 2015 at the age of 47, shortly after his father had also been diagnosed.

"I was so lucky that my cancer was picked up at a very early stage. I was young and fit, with no symptoms. A year after my treatment finished, I was told it had been successful. My dad wasn't so fortunate. He was diagnosed with advanced prostate cancer and passed away at 80. His experience, and mine, showed me the importance of early diagnosis."

Why we need more research into prostate cancer

We're proud of the research advances we've made over the last 20 years. Our scientists discovered the drug abiraterone; identified genetic variants that influence risk of developing the disease; and pioneered new, more precise forms of radiotherapy. But despite our research advances, some prostate cancers remain difficult to treat. This includes those diagnosed at a later stage and those more aggressive tumours, which can spread quickly and evolve to resist treatment.

That's why we urgently need better ways to detect prostate cancer earlier, predict drug resistance, and develop smarter, more personalised treatments. Your gift will help our world-leading researchers unravel the complexity of prostate cancer, to give men precise and personalised care with the right treatments at the right time, to live longer and healthier lives.

Professor Eeles's goal is to develop new tests that could be used in prostate cancer screening, helping to identify men at a higher risk. Her team showed that a simple saliva test, carried out at home, was more accurate at identifying future risk of prostate cancer for some men than the current standard blood test. 

Building on this success, they recently launched a major new study to find out whether an improved version of this test – now suitable for more diverse groups, including Black men and younger men – can help detect more cancers earlier in men at higher risk. 

Tackling drug resistance

Our research underpinned the development of olaparib, a drug that revolutionised treatment for people with BRCA-related cancers. In a recent study, Professor Johann de Bono's team showed that changes which can be spotted with a simple blood test can reveal how long a prostate cancer patient will respond to olaparib. 

The ability to predict when – and how – patients will stop responding to olaparib could help doctors personalise treatment, and in the future, guide the development of new drugs to outsmart resistance – keeping us one step ahead of prostate cancer.

Professor Johann de Bono in the laboratory, smiling.

Creating smarter, kinder treatments for every man

Our scientists are at the forefront of precision cancer medicine – developing more effective treatments with fewer side effects.

Laboratory studies co-led by Dr Adam Sharp and Professor Johann de Bono showed that NXP800 – a new drug which targets a ‘master switch’ that cancer cells hijack to support their growth – slowed prostate cancer cell growth. This innovative drug could potentially also benefit men with advanced prostate cancer that has stopped responding to standard hormone therapy.

A study co-led by Professor Emma Hall has found that men with intermediate-risk, localised prostate cancer can be treated just as effectively with five sessions of higher-dose radiation therapy as with several weeks of standard treatment. Using stereotactic body radiotherapy (SBRT), which targets tumours with pinpoint accuracy, patients can receive a highly effective treatment with far fewer hospital visits. 

A study co-led by Professor Nick James has shown that a new artificial intelligence (AI) test can select which men with high-risk prostate cancer that has not spread will require the life-extending drug abiraterone. In the STAMPEDE trial, the team found that three out of four men could be spared unnecessary treatment, making the drug – discovered by our scientists – more affordable for the NHS.

Your gift can help every man with prostate cancer live longer, healthier lives

Help someone's dad, grandad, brother, uncle, partner, or friend survive prostate cancer. Your support will help fund life-saving research – so that every man can spend more precious time with their loved ones.

Make a donation

Your gift of research can help transform the lives of every man with prostate cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

Your gift of research can help transform the lives of every man with prostate cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

 Related news and blogs

21/12/25 - by

Richard Ware, 56, was diagnosed with stage 4 prostate cancer in 2022. Last December, he was told that it had spread to his brain. Following his diagnosis, Richard found out that he carries the BRCA2 gene mutation and for the past 10 months he has been treated with olaparib, the discovery and development of which was underpinned by research at the ICR.

My symptoms first started in 2021. I was getting up to wee more often in the night and I noticed that the flow of my urine was very slow.  I went to my GP who diagnosed a urine infection, and I was sent home with antibiotics.  But my symptoms continued for several months and after my fourth visit to the doctor, I was offered a physical prostate exam and a PSA (prostate-specific antigen) test which is used to help check for prostate conditions. My PSA test came back with slightly raised results but as the GP could feel nothing unusual during the physical exam, I was told there was no reason to be concerned.

However, I continued to go back and forth to the GP as my symptoms persisted. By January 2022, I was finding it harder to wee and it was stinging when I passed urine. I had never really heard of the prostate, but when my wife and I Googled my symptoms, I began to suspect that this could be the problem.  Subsequent PSA tests showed my levels had gone up slightly, but they were never super high, which I have subsequently learned was quite unusual given how advanced my cancer was.

By April, I noticed that I was only ejaculating very tiny amounts of fluid. At this point, I was fast-tracked to see a urologist and an MRI scan clearly revealed I had prostate cancer. I had suspected this might be the case, but it was shocking to hear that it had already spread outside my prostate. A bone scan revealed that I had traces of cancer in my pelvis, although thankfully it had not spread to my soft tissue.

“The doctors told me it was incurable, but I was up for the fight”

Hearing you have stage 4 prostate cancer is tough.  But I was determined to beat it and fight with everything I had.  I was not going to let it change my life. The doctors told me it was incurable, but I was up for the fight. I believed in the developments of science and the treatments available to me – and I have stuck by this belief ever since.

I was put on hormone treatment immediately and had six doses of chemotherapy. When this finished towards the end of September 2022, I was told it had worked very well but I was offered a course of radiotherapy to follow up and give me the best chance of keeping the cancer away. In November 2023, I was told I was in remission. I remember getting off the phone feeling so relieved and happy. Sadly, I couldn’t fully celebrate my good health, as a few hours later I learned that my father had passed away.

In February 2024, I noticed a hazelnut-sized lump on my chest in the upper part of my sternum. It was growing very quickly, so much so that I struggled to do my top button up. Initially, my doctors were not concerned, believing that it was unrelated to my cancer. However, by the time it had grown to the size of a plum, I was referred to a neck specialist. A biopsy revealed that it was indeed cancer, but I was told it was unlikely to have spread from my prostate.  Further scans showed there were lumps in the back of my neck and base of my spine too – although I couldn’t feel these at all. 

I was immediately treated with an intense course of radiotherapy – daily treatments over a period of one or two weeks.  To the surprise of my doctors, this totally dissolved the tumours, and I was given the all-clear a few weeks later.  At this point, my oncologist gave me the nickname ‘Mr Unique.’  It was clear that not only did my cancer present itself in very unusual ways, but my responses to all the treatments were unusual too.  I was told that my cancer was sensitive and fast-growing, but that it also reacted quickly and well to treatment. I was put on abiraterone, a drug which was discovered and developed by the ICR, and goserelin (Zoladex) hormone injections every four weeks.

Our pioneering research is transforming the lives of men with prostate cancer. But too many lives are still lost. By supporting us today, you can help our scientists make more discoveries, develop more effective treatments – and give hope to every dad, brother, uncle, partner or friend with prostate cancer.


Support us

 

“I put cancer to the back of my mind”

In June 2024, my daughter got married. It was an incredible day.  After everything I had been through and with all the dancing I did that night, I was exhausted. But I looked well. I felt well.  I put my cancer to the back of my mind and enjoyed every minute of the celebrations. I put my ill health behind me and booked a family holiday to Cornwall for 2025.

But in November, I started getting headaches. I had no other symptoms, and the headaches were not very severe. I assumed they could be a side-effect of the Zoladex but was told by my doctors that this was unlikely.

In December, I was changing jobs at work. I had never suffered with stress, but I started to get feelings of anxiety. Then I started slurring my words. I have never been a drinker or a smoker, but on several occasions, I was asked if I’d been drinking.  I took myself to A&E, but after several hours of waiting in a corridor, I discharged myself and went home. I learned that if I slowed down my speech, I could stop the slurring, so I carried on as normal.

I’d always fancied a classic scooter, so after everything I had been through, I decided to treat myself to a 1960s Lambretta.  I passed my licence that would allow me to drive it. Little did I know, I had taken the test with a brain tumour.

Then one day in December, I started being sick and again had a headache. My wife was not happy and called NHS 111 for medical advice. They organised an ambulance to take me to A&E immediately.  My daughter came along with me. I was on the verge of being discharged with stress and anxiety, when she requested a CT scan on my brain. Two hours later, I was told I had a brain tumour the size of a ping-pong ball.

I had surgery the following day to successfully remove it. My slurring immediately stopped – in fact, I was singing fluently while in recovery!  But before I was discharged from hospital, I had an MRI scan which revealed 16 micro tumours in my brain.  These could not be removed with an operation, so I was treated with CyberKnife radiation therapy. 

A biopsy on my original tumour revealed it had formed as a result of my prostate cancer spreading. I was told this is quite rare.  It also revealed that tissue from my tumour tested positive for the BRCA2 gene mutation.  As a result, I was put on the targeted treatment olaparib, which had been released to NHS prostate cancer patients just months before - and I have been on this ever since.

“There is no question that I am here because of cancer research”

Thankfully, my current treatment seems to be helping. Ten months on, my three-monthly scans have shown no new tumour growth. My medical team says it is remarkable.  Even they did not expect this.  My mum calls me ‘the bionic man.’  I am incredibly grateful for the support of my family and all three of my  daughters  throughout this journey.

It is so worrying waiting for the results of scans every few months – even when I feel well, it is scary to think what they might find.  I have been beating this disease every time it rears its ugly head, but even though I am confident and upbeat and determined to win, I cannot help worrying about facing another setback.

In the meantime, I aim to live every day as normally as I can and I try not to worry until the day I am told there is nothing more they can do for me. My only frustration is not being allowed to drive, especially as someone who has worked in the motor trade all my life.

I am praying and hoping that scientists will come up with a new treatment when I next need it. I am very fortunate that two new drugs – abiraterone and olaparib – were available to me just when I needed them.   I hope that something will be developed that will be able to stop this disease.  What worries me most, is that scientists will manage to develop an incredible treatment, but that the cost of it will mean it won’t be made available to people who need it.

I’m still here despite everything and I am leading as normal a life as possible. I am back at work and looking forward to becoming a grandad for the first time early next year. Of course, I take the rough with the smooth and it has not been plain sailing. I deal every day with the side effects of my medications. But I am still on this planet and feel very blessed to be on the drugs I am.

I know I shouldn’t be here. But thanks to new medication and scientific advances, I am.  There is no question that I am here because of cancer research. I would be dead without it. I have a good feeling about 2026 and I have a lot to live for.  I cannot appreciate enough what cancer researchers are doing to help people to stay alive for longer. I cannot work out how I am in the position I am in – but I know that it is thanks to the amazing work being done by scientists who are making new discoveries every day.

We urgently need better ways to detect prostate cancer earlier, predict drug resistance, and develop smarter, more personalised treatments. Donate today to fund more groundbreaking discoveries and help ensure that every man with prostate cancer can live longer, healthier lives:


Donate now